Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Karyopharm Therapeutics ( (KPTI) ) has shared an announcement.
On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors of Karyopharm Therapeutics Inc., announced his resignation effective September 8, 2025, due to competing professional demands. Dr. Mirza’s resignation is not related to any disagreements with the company, and he is also stepping down from his role as Chief Oncologist at Copenhagen University National Medical Center to pursue a new executive role in the industry. Consequently, the consulting agreement between Karyopharm and Mirza Consulting was terminated as of September 8, 2025.
The most recent analyst rating on (KPTI) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.
Spark’s Take on KPTI Stock
According to Spark, TipRanks’ AI Analyst, KPTI is a Neutral.
Karyopharm Therapeutics’ overall stock score is primarily impacted by its weak financial performance, which poses significant risks. While technical indicators show bullish momentum, valuation concerns and financial constraints weigh heavily. Strategic initiatives and clinical progress offer some optimism, but the company’s financial health remains a critical issue.
To see Spark’s full report on KPTI stock, click here.
More about Karyopharm Therapeutics
Average Trading Volume: 164,241
Technical Sentiment Signal: Sell
Current Market Cap: $53.85M
See more insights into KPTI stock on TipRanks’ Stock Analysis page.